

ANTI-HYPERGLYCEMIC ALLIANCE



Dapagliflozin

VICEMIC-OD

Vildagliptin Sustained Release Tablets 100 mg

VICEMIC-D 5

Vildagliptin (As sustained release) 100 mg + Dapagliflozin 5 mg Tablets

VICEMIC-D 10

Vildagliptin (As sustained release) 100 mg + Dapagliflozin 10 mg Tablets

VICEMIC-OD

Vildagliptin Sustained Release Tablets 100 mg

VICEMIC-D5

Vildagliptin (As sustained release) 100 mg + Dapagliflozin 5 mg Tablets

VICEMIC-D 10

Vildagliptin (As sustained release) 100 mg + Dapagliflozin 10 mg Tablets

Description:

Vicemic-OD: Each Sustained Release Tablets contains Vildagliptin 100 mg

Vicemic-D 5: Each Bilayered Tablets contains Vildagliptin (As sustained release) 100 mg and Dapagliflozin 5 mg

Vicemic-D 10: Each Bilayered Tablets contains Vildagliptin (As sustained release) 100 mg and Dapagliflozin 10 mg

Indication:

As an adjunct to diet & exercise to improve glycemic control in adults with type-2 diabetes mellitus.


Mechanism of action:

Dapagliflozin:

- By inhibiting SGLT2, Dapagliflozin blocks reabsorption of filtered glucose in the kidney, increasing urinary glucose excretion and reducing blood glucose levels.
- This excretion allows for better glycemic control and potentially weight loss in patients with diabetes mellitus.

Vildagliptin:

- Vildagliptin binds covalently to the catalytic site of DPP-4, eliciting prolonged enzyme inhibition. This raises intact GLP-1 levels (Incretins hormone), both after meal ingestion and in the fasting state.
- GLP-1 leads to insulin secretion and inhibit glucagon secretion in a glucose-dependent manner.



Dosage and Administration:

Vicemic-OD/ D 5/ D 10: Once a daily or as prescribed by physician.

Presentation:

Vicemic-OD/ D 5/ D 10: Available as 10 tablets in a strip.

SGLT2= sodium-glucose Cotransporter-2; DPP-4= Dipeptidyl peptidase-4; GLP-1= glucagon-like peptide-1

